DR. CLIFFORD GEORGE RISK, M.D., PH.D.
Osteopathic Medicine at Bolton St, Marlboro, MA
License number
Massachusetts 47576
Category
Medical Practice
Type
Legal Medicine
License number
Massachusetts 47576
Category
Osteopathic Medicine
Type
Pulmonary Disease
Address
Address
320 Bolton St SUITE 101, Marlboro, MA 01752
Phone
(508) 481-4288
(508) 624-7228 (Fax)
(508) 624-7228 (Fax)
Professional information
Clifford George Risk, Marlborough MA
Specialties:
Pulmonologist
Address:
320 Bolton St, Marlborough, MA 01752
Education:
University of California Irvine, School of Medicine - Doctor of Medicine
Boston Medical Center - Fellowship - Pulmonary Disease (Internal Medicine)
Boston Medical Center - Fellowship - Pulmonary Disease (Internal Medicine)
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Pulmonary Disease (Internal Medicine), American Board of Internal Medicine Sub-certificate in Sleep Medicine (Internal Medicine)
Dr. Clifford G Risk, Marlborough MA - MD (Doctor of Medicine)
Specialties:
Critical Care Medicine, Pulmonology, Sleep Medicine
Address:
Dr. Clifford Risk, MD
320 Ste STE 100, Marlborough 01752
(508) 481-4288 (Phone)
320 Ste STE 100, Marlborough 01752
(508) 481-4288 (Phone)
Certifications:
Critical Care Medicine, 1989, Internal Medicine, 1983, Pulmonary Disease, 1984, Sleep Medicine, 2011
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Dr. Clifford Risk, MD
320 Ste STE 100, Marlborough 01752
Metrowest Medical Center
115 Lincoln St, Framingham 01702
Marlborough Hospital
157 Union St, Marlborough 01752
320 Ste STE 100, Marlborough 01752
Metrowest Medical Center
115 Lincoln St, Framingham 01702
Marlborough Hospital
157 Union St, Marlborough 01752
Education:
Medical School
University of California At Irvine / California College of Medicine & Surgery
Graduated: 1977
U Calif Irvine Med Ctr
Boston Medical Center
University of California At Irvine / California College of Medicine & Surgery
Graduated: 1977
U Calif Irvine Med Ctr
Boston Medical Center
Methods For Treating Chronic Obstructive Pulmonary Disease
US Patent:
2010024, Sep 30, 2010
Filed:
Jun 30, 2006
Appl. No.:
11/917572
Inventors:
Clifford G. Risk - Marlborough MA, US
International Classification:
A61K 39/395, A61P 11/00
US Classification:
4241331
Abstract:
The present invention provides methods of treating a mammal having chronic obstructive pulmonary disease (COPD), independent of both smoking status and asthma status/with a therapeutically effective amount of an anti-IgE Ênoiety. In accordance with the invention, COFD patients with an elevated serum IgE level may benefit from the treatment methods disclosed. In certain instances, the methods of the disclosure have been found, to be useful ioÊ the treatment of COPD patients regardless of their skin test results arid/or in vitro reactivity to a perennial aeroalleigen. Anti-EgE moieties, in accordance With the invention, include but are not limited to any IgG antibody that selectively binds to a given mammal iirunuitoglobulln E (e.g., human imntnnoglQbulin E) such as humanized arrti-IgEy hmuanized murine monoclonal antibody, and/or Qmalizumab.
Methods For Treating Chronic Obstructive Pulmonary Disease
US Patent:
2012007, Mar 22, 2012
Filed:
Nov 28, 2011
Appl. No.:
13/305222
Inventors:
Clifford G. Risk - Marlborough MA, US
International Classification:
A61K 39/395, A61P 11/00
US Classification:
4241331
Abstract:
The present invention provides methods of treating a mammal having chronic obstructive pulmonary disease (COPD), independent of both smoking status and asthma status, with a therapeutically effective amount of an anti-IgE moiety. In accordance with the invention, COPD patients with an elevated serum IgE level may benefit from the treatment methods disclosed. In certain instances, the methods of the disclosure have been found to be useful for the treatment of COPD patients regardless of their skin test results and/or in vitro reactivity to a perennial aeroallergen. Anti-IgE moieties, in accordance with the invention, include but are not limited to any IgG antibody that selectively binds to a given mammal immunoglobulin E (e.g., human immunoglobulin E) such as humanized anti-IgE, humanized murine monoclonal antibody, and/or Omalizumab.